NCT02062645View on ClinicalTrials.gov

Study of Efficacy and Safety of CVAA489 in Hypertensive Patients

PHASE4CompletedINTERVENTIONAL
Enrollment

115

Participants

Timeline

Start Date

February 28, 2014

Primary Completion Date

September 30, 2015

Study Completion Date

September 30, 2015

Conditions
Essential Hypertension
Interventions
DRUG

amlodipine/valsartan

Fixed combination of amlodipine and valsartan in tablet; 5/160/mg, 10/160 mg

Trial Locations (8)

20070

Novartis Investigative Site, Kinikli / Denizli

33079

Novartis Investigative Site, Mersin

34098

Novartis Investigative Site, Fatih / Istanbul

38039

Novartis Investigative Site, Talas / Kayseri

41380

Novartis Investigative Site, Kocaeli

44280

Novartis Investigative Site, Malatya

06100

Novartis Investigative Site, Ankara

Unknown

Novartis Investigative Site, Çanakkale

Sponsors
All Listed Sponsors
lead

Novartis Pharmaceuticals

INDUSTRY